Assessment of A1-PI dose-exposure and exposure-response relationships in patients with Alpha-1 antitrypsin inhibitor deficiency

Michael Tortorici (King of Prussia, United States of America), Michael A. Tortorici, Zhenling Yao, James A. Rogers, Oliver Vit, Martin Bexon, Robert Sandhaus, Jonathan Burdon, Eeva Piitulainen, Niels Seersholm, James Stocks, N. Gerard McElvaney, Kenneth R. Chapman, Jonathan Edelman

Source: International Congress 2015 – New data on established treatments for COPD
Session: New data on established treatments for COPD
Session type: Poster Discussion
Number: 1485
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Michael Tortorici (King of Prussia, United States of America), Michael A. Tortorici, Zhenling Yao, James A. Rogers, Oliver Vit, Martin Bexon, Robert Sandhaus, Jonathan Burdon, Eeva Piitulainen, Niels Seersholm, James Stocks, N. Gerard McElvaney, Kenneth R. Chapman, Jonathan Edelman. Assessment of A1-PI dose-exposure and exposure-response relationships in patients with Alpha-1 antitrypsin inhibitor deficiency. Eur Respir J 2015; 46: Suppl. 59, 1485

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Population pharmacokinetics of A1-PI in patients with Alpha-1 antitrypsin deficiency
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015


Degree of knowledge among physicians about the diagnosis and treatment of alpha-1 antitrypsin deficiency
Source: International Congress 2015 – COPD: chronic disease and comorbidities
Year: 2015

Pulmonary rehabilitation (PR) in patients with COPD due to alpha-1 antitrypsin deficiency (AATD): 15 years experience at the Maugeri Institute
Source: Annual Congress 2013 –The best posters in pulmonary rehabilitation
Year: 2013


Bronchiectasis but not emphysema is more prevalent in non-PiZ alpha-1 antitrypsin deficiency (AATD) COPD than in usual COPD
Source: International Congress 2014 – Genetics and environmental factors underlying asthma and COPD
Year: 2014


The Irish national alpha-1 antitrypsin deficiency targeted detection programme
Source: Annual Congress 2013 –Epidemiology of respiratory disease
Year: 2013


Long-term evolution of individuals with alpha1 antitrypsin deficiency from the Spanish registry
Source: International Congress 2015 – New frontiers in the management of interstitial and orphan lung diseases
Year: 2015


Diagnosis of alpha 1 antitrypsin deficiency in primary care
Source: International Congress 2015 – Management of COPD and other respiratory diseases in primary care
Year: 2015

Differences of disease phenotypes in individuals with alpha-1-antitrypsin deficiency with genotypes PiZZ and PiSZ - Analysis from the German registry
Source: International Congress 2016 – Phenotyping and monitoring airway diseases
Year: 2016

The national alpha-1 antitrypsin deficiency registry in Poland
Source: International Congress 2015 – Chronic airway disorders: miscellaneous aspects
Year: 2015


Specific airway resistance as a marker of early disease in alpha-1 antitrypsin deficiency
Source: International Congress 2015 – Lung function: exploring the boundaries of the respiratory system
Year: 2015

Screening for alpha-1 antitrypsin deficiency in Polish lung or liver disease patients
Source: Annual Congress 2011 - Lung development and neoplasia
Year: 2011

Prevalence of alpha-1 antitrypsin deficiency (AATD) and frequencies of alleles PI*S and PI*Z in patients with COPD in Brazil
Source: Annual Congress 2013 –Assessing the prevalence of COPD in the general population
Year: 2013

Identification of a novel SERPINA-1 mutation causing alpha-1 antitrypsin deficiency in a patient with severe dyspnea
Source: International Congress 2016 – Molecular targets in pulmonary disease
Year: 2016


Clinical features of alpha one antitrypsin deficiency in COPD
Source: Annual Congress 2012 - Inflammation in airway diseases: diagnosis and management
Year: 2012

COPD and alpha-1 antitrypsin deficiency emphysema: characteristics and survival after Lung Transplantation
Source: International Congress 2018 – Moving lung transplantation forward
Year: 2018

Predicting clinical course of alpha 1 anti-trypsin deficiency (AATD) using GOLD 2011 classification
Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations
Year: 2013


Lung function in relation to emphysema development in alpha-1 antitrypsin deficiency
Source: International Congress 2019 – Insights into physiological diagnostic services
Year: 2019


Screening of alpha-1 antitrypsin deficiency in a blood donors cohort of the North-Italian area
Source: International Congress 2015 – Prevalence of respiratory disease
Year: 2015


Research priorities in alpha-1 antitrypsin deficiency (AATD) for healthcare professionals
Source: Virtual Congress 2020 – COPD phenotypes
Year: 2020


Alpha-1 antitrypsin deficiency in patients with COPD/emphysema, bronchiectasis and asthma
Source: Virtual Congress 2020 – New biomarkers for management of obstructive diseases
Year: 2020